EQS-Adhoc: Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights
   EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action
   Marinomed Biotech AG evaluates possible 10% capital increase with
   exclusion of statutory subscription rights

   02-Sep-2024 / 17:46 CET/CEST
   Disclosure of an inside information acc. to Article 17 MAR of the
   Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS
   Group AG.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

   Korneuburg, Austria, 02. September 2024 - Marinomed Biotech AG (the
   “Company”) announces that the Management Board decided today to evaluate a
   capital increase of up to 154,053 new shares to be issued from the
   Authorized Capital 2024, subject to the direct exclusion of statutory
   subscription rights of existing shareholders, to finance the ongoing costs
   in the restructuring proceedings, to finance part of the restructuring
   plan proposal and for costs of continuing operations. This corresponds to
   up to 10% of the Company's existing share capital.

   For the purpose of the evaluation, the Management Board will enter into
   discussions with selected investors regarding the potential transaction
   and the transaction documentation. The actual implementation of the
   capital increase depends on the outcome of these discussions and is
   subject to further resolution by the Management Board and approval of the
   Supervisory Board. In addition, the restructuring proceedings require the
   approval of the restructuring administrator. These approvals have not yet
   been obtained.

   If the capital increase is implemented, the Management Board is
   considering a possible second capital increase of 10% of the Company's
   existing share capital, with exclusion of the statutory subscription
   rights of existing shareholders.

   +++ End of ad-hoc announcement +++ 
    

   End of Inside Information

   ══════════════════════════════════════════════════════════════════════════

   02-Sep-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com

   ══════════════════════════════════════════════════════════════════════════

   Language:    English
   Company:     Marinomed Biotech AG
                Hovengasse 25
                2100 Korneuburg
                Austria
   Phone:       +43 2262 90300
   E-mail:      office@marinomed.com
   Internet:    www.marinomed.com
   ISIN:        ATMARINOMED6
   WKN:         A2N9MM
   Listed:      Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
                Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
                (Official Market)
   EQS News ID: 1979933


    
   End of Announcement EQS News Service


   1979933  02-Sep-2024 CET/CEST

togel hongkong

togel hk

akun demo slot

result hk

By adminn